Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Chao Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3422-2763; OpenAlex author ID A5101440764. Sources: OpenAlex.

Their work

Papers
6 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2025: 2 papers · 2026: 4 papers

Papers 6

  1. Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 tri… Co-author DOI 10.1038/s41392-026-02966-0↗
  2. Rationally and in silico guided APOBEC3F-directed CBE for enhanced PDAC genetic therapy. Last author DOI 10.1038/s42003-026-09770-0↗
  3. Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilita… Co-author DOI 10.1136/gutjnl-2025-335790↗
  4. Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring. Co-author DOI 10.1158/2159-8290.cd-25-1627↗
  5. Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells. Co-author DOI 10.1038/s41422-025-01098-4↗
  6. Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-025-67197-3↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yukuan Feng · 5 shared papers, 2025–2026 · strength 1.06
  2. Jihui Hao · 5 shared papers, 2025–2026 · strength 1.05
  3. Yongjie Xie · 5 shared papers, 2025–2026 · strength 0.99
  4. Tianxing Zhou · 4 shared papers, 2025–2026 · strength 0.87
  5. Jun Yu · 4 shared papers, 2025–2026 · strength 0.84
  6. Xiuchao Wang · 4 shared papers, 2025–2026 · strength 0.80
  7. Tiansuo Zhao · 4 shared papers, 2025–2026 · strength 0.80
  8. Chongbiao Huang · 4 shared papers, 2025–2026 · strength 0.79
  9. Qingxiao Fang · 3 shared papers, 2026 · strength 0.66
  10. Shangheng Shi · 3 shared papers, 2026 · strength 0.62
  11. Song Gao · 3 shared papers, 2025–2026 · strength 0.60
  12. Yifei Wang · 2 shared papers, 2026 · strength 0.42
  13. Shengyu Yang · 1 shared paper, 2026 · strength 0.20
  14. Zhi Ji · 1 shared paper, 2026 · strength 0.20
  15. Jing Liu · 1 shared paper, 2026 · strength 0.20
  16. Rui Liu · 1 shared paper, 2026 · strength 0.20
  17. Chuntao Gao · 1 shared paper, 2026 · strength 0.20
  18. Jihui Hao · 1 shared paper, 2026 · strength 0.20
  19. Weidong Ma · 1 shared paper, 2026 · strength 0.20
  20. Kaiyuan Wang · 1 shared paper, 2025 · strength 0.19
  21. Bo Ni · 1 shared paper, 2025 · strength 0.19
  22. Ying Ma · 1 shared paper, 2025 · strength 0.19
  23. Chao Wu · 1 shared paper, 2025 · strength 0.18
  24. Shengnan Li · 1 shared paper, 2025 · strength 0.18
  25. Weishuai Liu · 1 shared paper, 2025 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.